Related Experiment Video
Updated: Sep 15, 2025

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
Re-consent practices in biobanks in Japan: current status and stakeholder perspectives
Hiroko Terui-Kohbata1,2, Hiyori Ueda3, Masayuki Yoshida4,3
1Life-Science and Bioethics Research Center, Institute of Science Tokyo, Tokyo, Japan. kohbbec@tmd.ac.jp.
Insights
Re-consent for pediatric research participants transitioning to adulthood is crucial but challenging. Japanese biobanks show low re-consent rates, highlighting ethical and logistical hurdles in genomic data sharing.
Area of Science:
- Genomics
- Biobanking
- Pediatric Research
Background:
- Longitudinal pediatric biobank research requires participant re-consent upon reaching adulthood.
- Re-consent ensures continued informed participation and ethical data sharing.
- Genomic data sharing in rare pediatric diseases necessitates robust consent processes.
Purpose of the Study:
- To examine current re-consent practices in Japanese biobanks for pediatric research.
- To explore stakeholder opinions on genomic data sharing and re-consent methods.
- To identify ethical and logistical challenges associated with re-consent acquisition.
Main Methods:
- Survey of 41 Japanese biobanks regarding pediatric sample handling and re-consent.
- Analysis of current re-consent acquisition practices and methods.
- Exploration of stakeholder perspectives on genomic data sharing.
Main Results:
- Only 25% of surveyed biobanks handling pediatric samples obtained re-consent.
- All re-consent was obtained via written informed consent.
- 71% of respondents acknowledged the necessity of re-consent, but methods varied.
- Stakeholders cited privacy concerns and administrative burden as key challenges.
Conclusions:
- Low re-consent rates in Japanese biobanks indicate significant challenges in pediatric genomic research.
- Ethical and logistical issues must be addressed to balance data sharing with participant rights.
- Developing optimal re-consent strategies requires ongoing stakeholder engagement and policy discussions.
Abstract:
Pediatric research in rare diseases relies on sharing biological specimens, clinical data, and analytical information among researchers. Re-consent is essential in longitudinal biobank (BB) research to ensure that pediatric participants remain informed and willing to continue. However, the issue of re-consent-obtaining consent once participants reach adulthood-remains a significant ethical concern. This study examined the current practices of re-consent acquisition in Japanese BBs and explores stakeholder opinions regarding genomic data sharing. A survey of 41 BBs revealed that only 25% of those handling pediatric samples obtained re-consent, all via written informed consent. Although 71% of respondents recognized the necessity of re-consent, the methods used to obtain it varied. Stakeholders identified ethical and logistical challenges, including privacy concerns and administrative burden. Various re-consent methods were suggested, with preferences depending on feasibility and ethical considerations. The findings highlight the need for policy discussions to balance data-sharing benefits with participant rights and privacy protection in pediatric genomic research. Determining optimal re-consent methods requires continued stakeholder engagement, including research participants and the public.
Related Concept Videos
Ethics in Research
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Ethics and Bioethics
Psychosurgery
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
Ethical Issues
Ethical Concerns in Healthcare:
Bioequivalence: Overview

